← daily scanner dashboard

#12 BIIB — BIOGEN INC.

A2_VCP_NEAR_PIVOT | as of 2026-10-02 | automated relative priority, not a published Minervini point formula

Relative priority40.83
RS rating77.50
Fundamental strength8.33
VCP score84.13
Pivot distance1.07%
AV confirmation100.00%complete
Technical chart for BIIB

Trend Template

price_above_sma150_and_sma200PASS
sma150_above_sma200PASS
sma200_rising_1mPASS
sma50_above_sma150_and_sma200PASS
price_above_sma50PASS
price_at_least_30pct_above_52w_lowPASS
price_within_25pct_of_52w_highPASS
rs_rating_at_least_70PASS

Trend Template metrics

close219.88
sma50215.29
sma150199.76
sma200195.19
sma200_1m_ago190.19
pct_above_52w_low59.33
pct_below_52w_high4.60
rs_rating77.50

VCP conditions

coherent_contraction_sequencePASS
enough_contractionsPASS
successive_ranges_inside_firstPASS
successive_depths_contractingPASS
final_contraction_tightPASS
base_depth_okPASS
resistance_area_tightPASS
volume_dryupFAIL
atr_contractingFAIL
price_tightPASS
near_pivotPASS

VCP metrics

num_contractions2.00
contraction_depths_pct[7.47, 3.45]
depth_ratios_vs_prior[0.462]
target_depth_ratio_roughly_half0.50
max_allowed_depth_ratio0.80
base_high225.80
base_low208.93
base_depth_pct7.47
base_duration_weeks4.10
resistance_spread_pct1.57
volume_dryup_ratio_10d_vs_50d1.27
atr_pct_recent2.48
atr_pct_prior3.04
atr_contraction_ratio0.82
tight_10d_range_pct7.41
raw_contraction_count12.00
raw_depths_pct[7.06, 9.77, 7.46, 5.04, 15.33, 8.74, 8.7, 5.27, 3.69, 4.16, 7.47, 3.45]
final_trough_age_bars9.00
selection_reasoncoherent_current_sequence
pivot_price222.25
distance_to_pivot_pct1.07
vcp_score_pct84.13
is_vcp_candidatePASS
breakout_on_volumeFAIL

Price / volume

return_1m_pct-1.25
return_3m_pct5.48
return_6m_pct23.99
return_12m_pct42.58
weighted_12m_momentum8.68
range_10d_pct7.41
range_20d_pct10.32
avg_volume_50d949,586
dollar_volume_50d208.79M
up_down_volume_ratio_50d1.02
accumulation_days_20d3.00
distribution_days_20d3.00

Fundamental overlay criteria

eps_growth_minimumPASS
sales_growth_positive_or_betterPASS
core_data_coveragePASS
eps_acceleratingPASS
sales_acceleratingFAIL
gross_margin_improving—
operating_margin_improving—

Minervini-oriented SEC fundamentals

eps_growth_yoy_pct31.10
eps_previous_q_yoy_growth_pct19.17
eps_acceleration_pts11.93
eps_annual_growth_pct-21.38
eps_cagr_3y_pct-25.04
sales_growth_yoy_pct1.93
sales_previous_q_yoy_growth_pct2.79
sales_acceleration_pts-0.87
sales_annual_growth_pct2.22
sales_cagr_3y_pct-0.94
gross_margin_pct—
operating_margin_pct—
pretax_margin_pct15.24
net_margin_pct12.89
gross_margin_yoy_change_pts—
operating_margin_yoy_change_pts—
roe_latest_fy_pct—
current_ratio3.06
debt_to_equity_pct—
cash_to_debt—
shares_outstanding—
adjusted_eps_growth_yoy_pct—
earnings_surprise_pct—
eps_estimate_revision_30d_pct—
analyst_count—
institutional_ownership_pct—
institutional_qoq_change_pct—
management_guidance_revision_pct—

SEC data quality

core_coverage_pct80.00
missing_core_metrics["equity", "shares_outstanding"]
selected_sec_tags{"accounts_payable": "us-gaap:AccountsPayableCurrent", "accounts_receivable": "us-gaap:AccountsReceivableNetCurrent", "capex": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment", "cash": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "cost_of_revenue": "us-gaap:CostOfRevenue", "current_assets": "us-gaap:AssetsCurrent", "current_liabilities": "us-gaap:LiabilitiesCurrent", "dividends_paid": null, "eps_basic": "us-gaap:EarningsPerShareBasic", "eps_diluted": "us-gaap:EarningsPerShareDiluted", "equity": "us-gaap:StockholdersEquity", "gross_profit": "us-gaap:GrossProfit", "inventory": "us-gaap:InventoryNet", "long_term_debt": null, "long_term_debt_current": "us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent", "net_income": "us-gaap:NetIncomeLoss", "operating_cash_flow": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "operating_income": "us-gaap:OperatingIncomeLoss", "pretax_income": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "r_and_d": "us-gaap:ResearchAndDevelopmentExpense", "revenue": "us-gaap:Revenues", "sga": "us-gaap:SellingGeneralAndAdministrativeExpense", "share_repurchases": "us-gaap:PaymentsForRepurchaseOfCommonStock", "shares_outstanding": "dei:EntityCommonStockSharesOutstanding", "short_term_debt": "us-gaap:DebtCurrent", "short_term_investments": "us-gaap:MarketableSecuritiesCurrent", "stock_based_comp": "us-gaap:ShareBasedCompensation", "total_assets": "us-gaap:Assets", "total_liabilities": "us-gaap:Liabilities", "weighted_avg_diluted_shares": "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding"}
unavailable_canonical_concepts["dividends_paid", "long_term_debt"]
warnings["Standalone Q4 income/EPS can be absent because 10-K statements are annual.", "Company-specific extension tags are not returned by CompanyFacts.", "Non-GAAP EPS, guidance, 13F ownership, Form 4 activity, and analyst estimates are separate modules."]

Reporting periods

latest_quarter_end2026-03-31
latest_quarter_filed2026-04-29
latest_fiscal_year_end2025-12-31
latest_balance_sheet_end2026-03-31

Company metadata

symbolBIIB
cik875,045
company_nameBIOGEN INC.
exchange—
sic2,836
sic_descriptionBiological Products, (No Diagnostic Substances)
fiscal_year_end1,231
as_of2026-10-04
sourceSEC EDGAR CompanyFacts + Submissions

Alpha Vantage enrichment

latest_reported_date2026-07-29
latest_reported_eps3.60
latest_estimated_eps3.04
latest_earnings_surprise_pct18.42
avg_earnings_surprise_4q_pct22.19
positive_earnings_surprises_4q4.00
earnings_surprise_quarters_available4.00
reported_eps_yoy_growth_pct-34.19
estimate_period2027-12-31
analyst_count_eps—
analyst_count_revenue—
eps_estimate_avg—
revenue_estimate_avg—
estimate_revision.eps_estimate_revision_up_trailing_7_days1.00
estimate_revision.eps_estimate_revision_up_trailing_30_days5.00
estimate_revision.eps_estimate_revision_down_trailing_30_days1.00
eps_revision_up_30d5.00
eps_revision_down_30d1.00
eps_revision_net_up_30d4.00
institutional.total_institutional_holders1,271
institutional.total_institutional_shares171.40M
institutional.holders_with_increased_holdings486.00
institutional.holders_with_decreased_holdings594.00
institutional.holders_with_unchanged_holdings191.00
institutional_holder_rows1,271
institutional_total_shares171.40M
endpoints_returned["EARNINGS", "EARNINGS_ESTIMATES", "INSTITUTIONAL_HOLDINGS"]

Alpha Vantage confirmation screen

latest_earnings_surprise_positivePASS
average_4q_earnings_surprise_positivePASS
positive_surprise_quartersPASS
analyst_coverage_present—
eps_revision_breadth_nonnegative_30dPASS
institutional_sponsorship_presentPASS

Alpha Vantage screen summary

statuscomplete
confirmation_score_pct100.00
available_criteria5.00
noteInformational post-Exp0 confirmation only; not part of validated Exp0 selection/ranking.

Alpha Vantage endpoint status

EARNINGScache_available
EARNINGS_ESTIMATEScache_available
INSTITUTIONAL_HOLDINGScache_available

Accepted VCP contractions

peak_datepeak_pricetrough_datetrough_pricedepth_pctdepth_ratio_vs_priorbars
2026-09-03225.802026-09-10208.937.47—4.00
2026-09-14222.252026-09-21214.593.450.465.00

Recent SEC filings

formfiling_dateaccession_numberprimary_document
10-Q2026-07-290000875045-26-000075biib-20260630.htm
8-K2026-07-290000875045-26-000073biib-20260729.htm
8-K2026-07-010000875045-26-000068biib-20260701.htm
8-K2026-06-100000950157-26-000700form8-k.htm
8-K/A2026-06-100000950157-26-000699form8-ka.htm
8-K2026-05-140001193125-26-222908d109852d8k.htm
10-Q2026-04-290000875045-26-000045biib-20260331.htm
8-K2026-04-290000875045-26-000042biib-20260429.htm
8-K2026-04-060000875045-26-000039biib-20260406.htm
8-K2026-03-310001193125-26-134889d14986d8k.htm
8-K2026-03-110000950157-26-000280form8-k.htm
8-K2026-02-110001193125-26-046803d937279d8k.htm

SEPA factors not covered by SEC + Yahoo

These remain manual or require another provider/module and are deliberately not guessed: